ENDING HIV
We are the only pharmaceutical company solely focused on combating, preventing, and ultimately eradicating HIV and AIDS, but of course, none of what we do can be achieved alone – we believe in the power of partnership.
We partner in research, in access and with the community because we believe that we are stronger together when it comes to working towards the UN target of ending the AIDS epidemic by 2030.
Of the 38 million people living with HIV globally, almost 75% live in low- and middle- income countries, and 27% are not on treatment.
We are committed to enabling access to our medicines to benefit people affected by HIV, regardless of their income, location, status, age or gender.
Despite advances in prevention, treatment and care, people living with HIV continue to face unique challenges that impact their quality of life daily. HIV stigma continues to persist, affecting those living with the virus as well as their support networks.
Despite progress, paediatric HIV remains a global issue, with children disproportionately affected by the HIV epidemic.
Latest statistics show there are 1.7m children under 15 years of age living with HIV, with only half having access to treatment.
We support a growing community of researchers, policy makers, community organisations, advocates and other stakeholders who are interested in studying current HIV care practices.
Our aim is to challenge the status quo, and shape health policy and practices that can lead to an HIV-free future.
OUR STORIES: SCIENCE AND INNOVATION
Discover the importance of representative research for HIV treatment for people living with HIV
Incredible progress has been made over the past four decades of the HIV epidemic. Gone are the “bad old days” of the epidemic when HIV was the leading cause of death for adults in the US between the ages of 25-44.
You don’t need a PhD to get in on the science with us! For too long, the latest in HIV research and science was limited to laboratories and medical congresses – far away from the lives of the people it impacted the most. With ViiV Healthcare’s Science on the Sofa, we’re changing how we talk about HIV science by breaking down complex concepts in a new way to make the science accessible for everyone.
NP-GBL-HVX-COCO-220017 November 2021.
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard or search for MHRA Yellowcard in the Google Play or Apple App store. By reporting side effects, you can help provide more information on the safety of this medicine.
If you are from outside the UK, you can report adverse events to GSK/ViiV by selecting your region and market, here.
